Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Adeona’s Alzheimer’s Disease Pivotal Clinical Study Results Abstract Accepted for Presentation at the American Academy of Neurology’s 63rd Annual Meeting

February 8, 2011 By Bio-Medicine.Org

ANN ARBOR, Mich., Feb. 8, 2011 /PRNewswire/ — Adeona
Pharmaceuticals, Inc. (Amex:
AEN
), a developer of innovative medicines for serious central
nervous system diseases, announced today that an abstract on the
Company’s pivotal clinical trial of its zinc and cysteine-based
product candidate being evaluated in patients with Alzheimer’s
disease and mild cognitive impairment has been accepted for
presentation at the 2011 American Academy of Neurology Annual
Meeting in April. The abstract will provide top line clinical trial
results, as well as the rationale and design of the pivotal
study.

Diana Pollock, M.D., Lead Principal Investigator of the trial at
Morton Plant Neuroscience Institute on the campus of Morton Plant
Hospital, is the first author on the abstract titled “Clinical
Trial Results of the First Controlled Clinical Trial of Zinc-Based
Therapy for Alzheimer’s Disease and Mild Cognitive Impairment.” The
poster presentation will be held from 2:00 to 6:30 p.m. on April
14, 2011 at the Hawaii Convention Center in Honolulu, Hawaii. Due
to conference restrictions with regard to the embargo policy
relating to clinical trial results, Adeona plans to present the
results of its pivotal clinical trial during this conference and
distribute a concurrent press release.

Adeona also announced that “reaZin™” has been
adopted as the new trademark for its zinc and cysteine-based oral
tablet currently under development as a prescription medical food
for the dietary management of Alzheimer’s disease and mild
cognitive impairment. Previously, Adeona’s zinc and cysteine-based
product candidate was called Zinthionein.

reaZin was selected as the new trademark as it is a
homophone to the word reason, a high level cognitive function
affected by Alzheimer’s disease that Adeona’s product candidate
seeks to address. In addition, the “Zin” root is suggestive of the
p

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech